Genoscience Pharma Is A Clinical Stage Biopharmaceutical Company Dedicated To Developing Innovative Therapies For Cancerfounded In 2001 By Drphilippe Halfonthe Company Initially Focused On Antiviral Treatments Before Shifting Its Emphasis To Oncology In 2012This Transition Was Driven By The Discovery Of A Novel Family Of Autophagy Inhibitors That Showed Potential Against Cancer Stem Cells The Company Specializes In Lysosomal Targeting Therapiescreating Small Molecule Drugs That Disrupt Lysosomal Function To Deprive Cancer Cells Of Essential Nutrientsgenoscience Pharma Also Develops Autophagy Inhibitors To Block The Recycling Process That Cancer Cells Use To Survive Under Stresstheir Clinical Stage Pipeline Includes Candidates Targeting Cancers With High Unmet Needssuch As Intrahepatic Cholangiocarcinomawith Ongoing Trials Noted As Recently As 2022Ae 2023Genoscience Pharma Aims To Address The Needs Of Patients With Treatment Resistant Or Advanced Stage Malignanciesfocusing On Cancers That Lack Effective Therapies
